Literature DB >> 23768868

Polymorphisms in JAK/STAT signaling pathway genes and risk of non-Hodgkin lymphoma.

Yingtai Chen1, Qing Lan, Tongzhang Zheng, Nan Zhao, Theodore R Holford, Catherine Lerro, Min Dai, Huang Huang, Jiaxin Liang, Shuangge Ma, Brian Leaderer, Peter Boyle, Stephen Chanock, Nathaniel Rothman, Yawei Zhang.   

Abstract

Impaired function of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway genes leads to immunodeficiency and various hematopoietic disorders. We evaluated the association between genetic polymorphisms (SNPs) in 12 JAK/STAT pathway genes (JAK3, STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, STAT6, SCOS1, SCOS2, SCOS3, and SCOS4) and NHL risk in a population-based case-control study of Connecticut women. We identified three SNPs in STAT3 (rs12949918 and rs6503695) and STAT4 (rs932169) associated with NHL risk after adjustment for multiple comparison. Our results suggest that genetic variation in JAK/STAT pathway genes may play a role in lymphomagenesis and warrants further investigation.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Case–control study; JAK/STAT signaling pathway; Non-Hodgkin lymphoma; Polymorphism

Mesh：

Substances：

Year:  2013        PMID： 23768868      PMCID： PMC3998836          DOI： 10.1016/j.leukres.2013.05.003

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  40 in total

Review 1.  STAT family of transcription factors in cytokine-mediated biological responses.

Authors:  K Takeda; S Akira
Journal:  Cytokine Growth Factor Rev       Date:  2000-09       Impact factor: 7.638

2.  Distribution of recombination crossovers and the origin of haplotype blocks: the interplay of population history, recombination, and mutation.

Authors:  Ning Wang; Joshua M Akey; Kun Zhang; Ranajit Chakraborty; Li Jin
Journal:  Am J Hum Genet       Date:  2002-10-15       Impact factor: 11.025

Review 3.  The non-Hodgkin lymphomas: a review of the epidemiologic literature.

Authors:  Dominik D Alexander; Pamela J Mink; Hans-Olov Adami; Ellen T Chang; Philip Cole; Jack S Mandel; Dimitrios Trichopoulos
Journal:  Int J Cancer       Date:  2007       Impact factor: 7.396

Review 4.  STATs in oncogenesis.

Authors:  T Bowman; R Garcia; J Turkson; R Jove
Journal:  Oncogene       Date:  2000-05-15       Impact factor: 9.867

5.  Collection of genomic DNA from adults in epidemiological studies by buccal cytobrush and mouthwash.

Authors:  M García-Closas; K M Egan; J Abruzzo; P A Newcomb; L Titus-Ernstoff; T Franklin; P K Bender; J C Beck; L Le Marchand; A Lum; M Alavanja; R B Hayes; J Rutter; K Buetow; L A Brinton; N Rothman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2001-06       Impact factor: 4.254

6.  Polymorphisms in pattern-recognition genes in the innate immunity system and risk of non-Hodgkin lymphoma.

Authors:  Wei Hu; Bryan A Bassig; Jun Xu; Tongzhang Zheng; Yawei Zhang; Sonja I Berndt; Theodore R Holford; H Dean Hosgood; Brian Leaderer; Meredith Yeager; Idan Menashe; Peter Boyle; Kaiyong Zou; Yong Zhu; Stephen Chanock; Qing Lan; Nathaniel Rothman
Journal:  Environ Mol Mutagen       Date:  2012-10-11       Impact factor: 3.216

Review 7.  STAT signaling in the pathogenesis and treatment of leukemias.

Authors:  T S Lin; S Mahajan; D A Frank
Journal:  Oncogene       Date:  2000-05-15       Impact factor: 9.867

Review 8.  Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention.

Authors:  Ralf Buettner; Linda B Mora; Richard Jove
Journal:  Clin Cancer Res       Date:  2002-04       Impact factor: 12.531

9.  Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2.

Authors:  J Schwaller; E Parganas; D Wang; D Cain; J C Aster; I R Williams; C K Lee; R Gerthner; T Kitamura; J Frantsve; E Anastasiadou; M L Loh; D E Levy; J N Ihle; D G Gilliland
Journal:  Mol Cell       Date:  2000-09       Impact factor: 17.970

10.  Immune mechanisms in non-Hodgkin lymphoma: joint effects of the TNF G308A and IL10 T3575A polymorphisms with non-Hodgkin lymphoma risk factors.

Authors:  Sophia S Wang; Wendy Cozen; James R Cerhan; Joanne S Colt; Lindsay M Morton; Eric A Engels; Scott Davis; Richard K Severson; Nathaniel Rothman; Stephen J Chanock; Patricia Hartge
Journal:  Cancer Res       Date:  2007-05-15       Impact factor: 12.701
View more
  4 in total

1.  STAT3 and STAT5b polymorphism contributes to breast cancer risk and clinical outcomes.

Authors:  Ling Zhao; Qingyuan Zhang; Xin Luan; Xu Huang; Shu Zhao; Hong Zhao
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

2.  Association between STAT3 polymorphisms and cancer risk: a meta-analysis.

Authors:  Ruicheng Yan; Fusheng Lin; Chao Hu; Shilun Tong
Journal:  Mol Genet Genomics       Date:  2015-06-11       Impact factor: 3.291

3.  IL-6, through p-STAT3 rather than p-STAT1, activates hepatocarcinogenesis and affects survival of hepatocellular carcinoma patients: a cohort study.

Authors:  Jung-Ta Kao; Chun-Lung Feng; Cheng-Ju Yu; Shu-Mei Tsai; Ping-Ning Hsu; Yao-Li Chen; Yi-Ying Wu
Journal:  BMC Gastroenterol       Date:  2015-04-25       Impact factor: 3.067

4.  Genetic polymorphisms of STAT3 correlated with prognosis in diffuse large B-cell lymphoma patients treated with rituximab.

Authors:  Yunfei Hu; Ning Ding; Xuan Jin; Lixia Feng; Lingyan Ping; Yuqin Song; Jun Zhu
Journal:  Cancer Cell Int       Date:  2014-03-13       Impact factor: 5.722
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.